- In the first study, patients who were given TELMISARTAN (blood pressure treatment), were no less likely to have another stroke than those in the placebo group.
- The second study showed that CLOPIDOGREL (blood thinner) was no more effective than aspirin combined with the anti-platelet drug DIPYRIDAMOLE in reducing the chance of a stroke.
- CLOPIDOGREL is sold by Bristol-Myers under the brand name PLAVIX and Boehringer makes DIPYRIDAMOLE.
- TELMISARTAN is sold by Boehringer and Bayer.
- Both studies were presented in the New England Journal of Medicine.

Healthcare sector headlines

• OPTS.UK Today 02:01am
  Optos PLC Reports FY08 Pretax $5.9M v $1.6M y/y, Rev $101M v $86.8M y/y- 14% growth in North America revenue - 61% growth in European revenue - 18% increase in devices installed worldwide to 3,983 - more...
  
• NOVN.SZ Today 01:55am
  Novartis AG Presents 200 abstracts at American Society of Hematology- Tasigna front-line data demonstrating potential in newly diagnosed patients with a life-threatening type of leukemia to be featured in two more...
  
• ROG.SZ Today 01:30am
  Roche Holding AG Agree with FDA on pathway towards U.S. approval of ACTEMRA for rheumatoid arthritis - FDA has provided further guidance on the requirements for the Biologics License Application (BLA) for ACTEMRA, more...
  
• CTIC Today 01:30am
  Cell Therapeutics Inc Zevalin Data to be Presented at ASH 2008- Co y announced presentations or posters of interest related to Zevalin(R) (ibritumomab tiuxetan) to be presented at the 50th Annual Meeting of the American more...
  
• EPCT Today 00:02am
  EpiCept Reports New Data on Benefits of Maintenance Therapy With Ceplene and interleukin-2 For AML Patients At ASH Annual Meeting